USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never ...

Truist lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $18 from $21 but keeps a Buy rating on the shares after its Q4 results ...

Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clin ...

Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 ; The Company established two business units in January 2025 aimed ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

Journal of Nuclear Medicine February 2025, jnumed.124.268835; DOI: https://doi.org/10.2967/jnumed.124.268835 ...

Original Medicare Part A covers radiation therapy received as an inpatient in the hospital, Part B covers radiation therapy received as an outpatient in a clinic, and Part D may cover oral ...

1 Comprehensive Cancer Center Eugène Marquis, Rennes, France 2 Univ Rennes, Inrae, Inserm, Institut NUMECAN (Nutrition, Métabolismes et Cancer) – UMR_A 1341, UMR_S 1241, Rennes, France Over the past ...

Immune checkpoint blockade (ICB) has been approved as first- or second-line therapy options in a broadening range of metastatic cancer and is increasingly explored in the treatment of early stage ...

The Fred Hutchinson Cancer Research Center published a popular science news article on their web-page "Fine-tuning radioimmunotherapy with an alpha-emitting radionuclide" in April 15, 2013, concerning ...